Evotec SE
Company Profile
Business description
Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.
Contact
Essener Bogen 7
Manfred Eigen Campus
Hamburg22419
DEUT: +49 40560810
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2025
Employees
4,766
Stocks News & Analysis
stocks
Uber flexes its network effect and delivers strong result
stocks
Ask the analyst: Are Qantas shares a value trap?
stocks
Palantir earnings: Blockbuster growth amid high expectations
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 9,105.40 | 5.70 | -0.06% |
CAC 40 | 7,635.03 | 13.99 | 0.18% |
DAX 40 | 23,924.36 | 78.29 | 0.33% |
Dow JONES (US) | 44,193.12 | 81.38 | 0.18% |
FTSE 100 | 9,164.31 | 21.58 | 0.24% |
HKSE | 24,996.78 | 86.15 | 0.35% |
NASDAQ | 21,169.42 | 252.87 | 1.21% |
Nikkei 225 | 41,149.02 | 354.16 | 0.87% |
NZX 50 Index | 12,925.57 | 45.41 | 0.35% |
S&P 500 | 6,345.06 | 45.87 | 0.73% |
S&P/ASX 200 | 8,835.90 | 7.80 | -0.09% |
SSE Composite Index | 3,638.39 | 4.39 | 0.12% |